Published in Nat Rev Genet on October 01, 2010
Cancer genome landscapes. Science (2013) 25.33
Charting a course for genomic medicine from base pairs to bedside. Nature (2011) 9.39
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Comparative analysis of RNA-Seq alignment algorithms and the RNA-Seq unified mapper (RUM). Bioinformatics (2011) 6.20
Statistical analysis of rare sequence variants: an overview of collapsing methods. Genet Epidemiol (2011) 6.18
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Repetitive DNA and next-generation sequencing: computational challenges and solutions. Nat Rev Genet (2011) 5.58
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30
A public genome-scale lentiviral expression library of human ORFs. Nat Methods (2011) 4.98
KIF5B-RET fusions in lung adenocarcinoma. Nat Med (2012) 4.38
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia (2013) 3.93
De novo mutations in human genetic disease. Nat Rev Genet (2012) 3.81
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell (2013) 3.26
Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov (2013) 3.13
Medulloblastomics: the end of the beginning. Nat Rev Cancer (2012) 3.01
Making sense of cancer genomic data. Genes Dev (2011) 3.01
Pacific biosciences sequencing technology for genotyping and variation discovery in human data. BMC Genomics (2012) 2.92
Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. Nat Struct Mol Biol (2013) 2.84
De novo discovery of mutated driver pathways in cancer. Genome Res (2011) 2.72
Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat Med (2013) 2.70
Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer (2011) 2.64
DNA replication timing and long-range DNA interactions predict mutational landscapes of cancer genomes. Nat Biotechnol (2011) 2.62
Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol (2013) 2.59
Sequencing technologies and genome sequencing. J Appl Genet (2011) 2.52
Emerging patterns of somatic mutations in cancer. Nat Rev Genet (2013) 2.50
Extremely low-coverage sequencing and imputation increases power for genome-wide association studies. Nat Genet (2012) 2.50
Genome-wide copy number analysis of single cells. Nat Protoc (2012) 2.47
RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res (2012) 2.41
A genomics-based classification of human lung tumors. Sci Transl Med (2013) 2.41
Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer (2011) 2.34
Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab (2013) 2.34
Sequencing studies in human genetics: design and interpretation. Nat Rev Genet (2013) 2.27
Predicting outcomes in radiation oncology--multifactorial decision support systems. Nat Rev Clin Oncol (2012) 2.23
The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res (2012) 2.19
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clin Cancer Res (2015) 2.12
Computational tools for copy number variation (CNV) detection using next-generation sequencing data: features and perspectives. BMC Bioinformatics (2013) 2.07
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. JAMA (2015) 2.02
Effects of sequence variation on differential allelic transcription factor occupancy and gene expression. Genome Res (2012) 1.99
Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest (2011) 1.99
THetA: inferring intra-tumor heterogeneity from high-throughput DNA sequencing data. Genome Biol (2013) 1.98
Personalized medicine: new genomics, old lessons. Hum Genet (2011) 1.85
Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis (2012) 1.84
A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut (2013) 1.80
Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells? Int J Cancer (2011) 1.79
The cancer antigenome. EMBO J (2012) 1.78
qpure: A tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles. PLoS One (2012) 1.77
The rise of a digital immune system. Gigascience (2012) 1.74
Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing. J Vis Exp (2013) 1.68
Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest (2012) 1.64
Inferring clonal evolution of tumors from single nucleotide somatic mutations. BMC Bioinformatics (2014) 1.62
DNA qualification workflow for next generation sequencing of histopathological samples. PLoS One (2013) 1.57
Cancer genome-sequencing study design. Nat Rev Genet (2013) 1.55
Existing and emerging technologies for tumor genomic profiling. J Clin Oncol (2013) 1.52
A comparative analysis of algorithms for somatic SNV detection in cancer. Bioinformatics (2013) 1.51
Clonal evolution in hematological malignancies and therapeutic implications. Leukemia (2013) 1.50
The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene (2014) 1.49
Somatic retrotransposition in human cancer revealed by whole-genome and exome sequencing. Genome Res (2014) 1.47
Molecular biology of lung cancer: clinical implications. Clin Chest Med (2011) 1.47
Fluorescence in situ hybridization with high-complexity repeat-free oligonucleotide probes generated by massively parallel synthesis. Chromosome Res (2011) 1.46
Clinical analysis and interpretation of cancer genome data. J Clin Oncol (2013) 1.44
Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet (2012) 1.41
Functional genomic analysis of chromosomal aberrations in a compendium of 8000 cancer genomes. Genome Res (2012) 1.39
Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med (2015) 1.37
Comparing somatic mutation-callers: beyond Venn diagrams. BMC Bioinformatics (2013) 1.35
Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov (2013) 1.34
Improving the prediction of the functional impact of cancer mutations by baseline tolerance transformation. Genome Med (2012) 1.32
Next-generation sequencing to guide cancer therapy. Genome Med (2015) 1.31
Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia. PLoS Genet (2013) 1.29
The new sequencer on the block: comparison of Life Technology's Proton sequencer to an Illumina HiSeq for whole-exome sequencing. Hum Genet (2013) 1.27
CRAC: an integrated approach to the analysis of RNA-seq reads. Genome Biol (2013) 1.26
An empirical Bayesian framework for somatic mutation detection from cancer genome sequencing data. Nucleic Acids Res (2013) 1.24
Application of next generation sequencing to human gene fusion detection: computational tools, features and perspectives. Brief Bioinform (2012) 1.23
Genetic changes in squamous cell lung cancer: a review. J Thorac Oncol (2012) 1.23
Reduced local mutation density in regulatory DNA of cancer genomes is linked to DNA repair. Nat Biotechnol (2013) 1.21
A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Mol Cancer Ther (2014) 1.21
Quantifying tumor heterogeneity in whole-genome and whole-exome sequencing data. Bioinformatics (2014) 1.20
Coverage bias and sensitivity of variant calling for four whole-genome sequencing technologies. PLoS One (2013) 1.20
Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. Proc Natl Acad Sci U S A (2012) 1.17
Advancing precision medicine for prostate cancer through genomics. J Clin Oncol (2013) 1.16
Characterizing mutational heterogeneity in a glioblastoma patient with double recurrence. PLoS One (2012) 1.16
Chromatin immunoprecipitation and high-throughput sequencing from paraffin-embedded pathology tissue. Nat Protoc (2011) 1.15
Advances for studying clonal evolution in cancer. Cancer Lett (2013) 1.14
Identification of somatic mutations in cancer through Bayesian-based analysis of sequenced genome pairs. BMC Genomics (2013) 1.13
Sequence to Medical Phenotypes: A Framework for Interpretation of Human Whole Genome DNA Sequence Data. PLoS Genet (2015) 1.12
Whole-exome sequencing studies of nonhereditary (sporadic) parathyroid adenomas. J Clin Endocrinol Metab (2012) 1.12
A framework for organizing cancer-related variations from existing databases, publications and NGS data using a High-performance Integrated Virtual Environment (HIVE). Database (Oxford) (2014) 1.12
Leukemia gene atlas--a public platform for integrative exploration of genome-wide molecular data. PLoS One (2012) 1.11
Exome sequencing reveals comprehensive genomic alterations across eight cancer cell lines. PLoS One (2011) 1.10
Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing. PLoS One (2013) 1.10
Role of non-coding sequence variants in cancer. Nat Rev Genet (2016) 1.10
Pulmonary adenocarcinoma: a renewed entity in 2011. Respirology (2012) 1.09
Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. Leukemia (2013) 1.08
A high-dimensional, deep-sequencing study of lung adenocarcinoma in female never-smokers. PLoS One (2013) 1.08
SomamiR: a database for somatic mutations impacting microRNA function in cancer. Nucleic Acids Res (2012) 1.08
Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discov (2011) 1.07
Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. Pharmgenomics Pers Med (2014) 1.06
Integrated RNA and DNA sequencing improves mutation detection in low purity tumors. Nucleic Acids Res (2014) 1.05
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol (2009) 235.12
The Sequence Alignment/Map format and SAMtools. Bioinformatics (2009) 232.39
Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (2009) 190.94
Genome sequencing in microfabricated high-density picolitre reactors. Nature (2005) 150.21
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 97.51
Accurate whole human genome sequencing using reversible terminator chemistry. Nature (2008) 90.20
A method and server for predicting damaging missense mutations. Nat Methods (2010) 78.53
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Serial analysis of gene expression. Science (1995) 60.15
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
The complete genome of an individual by massively parallel DNA sequencing. Nature (2008) 52.81
Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics (2010) 52.01
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Human non-synonymous SNPs: server and survey. Nucleic Acids Res (2002) 50.45
SSAHA: a fast search method for large DNA databases. Genome Res (2001) 48.64
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet (2008) 43.63
Circos: an information aesthetic for comparative genomics. Genome Res (2009) 40.02
SOAP2: an improved ultrafast tool for short read alignment. Bioinformatics (2009) 39.47
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Next-generation DNA sequencing. Nat Biotechnol (2008) 34.95
Targeted capture and massively parallel sequencing of 12 human exomes. Nature (2009) 33.96
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
Exome sequencing identifies the cause of a mendelian disorder. Nat Genet (2009) 32.06
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Predicting deleterious amino acid substitutions. Genome Res (2001) 28.95
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol (2009) 27.17
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
The cancer genome. Nature (2009) 23.13
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol (2009) 21.94
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science (2009) 21.24
Accurate multiplex polony sequencing of an evolved bacterial genome. Science (2005) 20.91
Genome-wide in situ exon capture for selective resequencing. Nat Genet (2007) 19.97
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 18.59
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature (2005) 18.43
BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat Methods (2009) 18.41
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Direct selection of human genomic loci by microarray hybridization. Nat Methods (2007) 17.73
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science (2008) 16.60
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics (2009) 16.04
Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics (2009) 15.08
A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A (1983) 14.73
A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics (2007) 14.25
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med (2009) 13.47
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Methods (2008) 12.56
Transcriptome sequencing to detect gene fusions in cancer. Nature (2009) 11.63
SHRiMP: accurate mapping of short color-space reads. PLoS Comput Biol (2009) 11.24
Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A (1982) 11.15
The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) 10.04
Signatures of mutation and selection in the cancer genome. Nature (2010) 9.75
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
BFAST: an alignment tool for large scale genome resequencing. PLoS One (2009) 7.48
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
Identification of ALK as a major familial neuroblastoma predisposition gene. Nature (2008) 7.38
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med (2006) 6.96
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80
Next-generation tag sequencing for cancer gene expression profiling. Genome Res (2009) 6.50
Massively parallel exon capture and library-free resequencing across 16 genomes. Nat Methods (2009) 6.36
Inferring tumor progression from genomic heterogeneity. Genome Res (2009) 6.09
Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med (2010) 6.08
Comment on "The consensus coding sequences of human breast and colorectal cancers". Science (2007) 5.88
Oncogenic mutations of ALK kinase in neuroblastoma. Nature (2008) 5.80
Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med (2009) 5.63
Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem (2005) 5.58
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature (2008) 5.32
Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A (2009) 5.30
High-resolution analysis of DNA copy number using oligonucleotide microarrays. Genome Res (2004) 5.24
Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res (2009) 4.92
Rules for making human tumor cells. N Engl J Med (2002) 4.84
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
LINE-1 retrotransposition activity in human genomes. Cell (2010) 4.60
Assessment of whole genome amplification-induced bias through high-throughput, massively parallel whole genome sequencing. BMC Genomics (2006) 4.55
Whole exome capture in solution with 3 Gbp of data. Genome Biol (2010) 4.23
SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors. Bioinformatics (2010) 4.02
Digital karyotyping. Proc Natl Acad Sci U S A (2002) 3.96
Mobile interspersed repeats are major structural variants in the human genome. Cell (2010) 3.60
Determinants of protein function revealed by combinatorial entropy optimization. Genome Biol (2007) 3.46
Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A (2008) 3.30
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 97.51
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol (2009) 27.17
International network of cancer genome projects. Nature (2010) 20.35
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science (2012) 17.12
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Calibrating a coalescent simulation of human genome sequence variation. Genome Res (2005) 15.04
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
New models of collaboration in genome-wide association studies: the Genetic Association Information Network. Nat Genet (2007) 13.76
Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature (2012) 13.71
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
A landscape of driver mutations in melanoma. Cell (2012) 12.61
High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Methods (2008) 12.56
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nat Genet (2008) 12.07
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 9.60
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. Nature (2012) 8.91
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
Outcome signature genes in breast cancer: is there a unique set? Bioinformatics (2004) 7.96
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Pan-cancer patterns of somatic copy number alteration. Nat Genet (2013) 7.73
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14
Ethical and practical guidelines for reporting genetic research results to study participants: updated guidelines from a National Heart, Lung, and Blood Institute working group. Circ Cardiovasc Genet (2010) 6.74
Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med (2014) 6.12
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet (2011) 5.58
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature (2012) 5.23
A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol (2011) 5.11
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
The genetic landscape of high-risk neuroblastoma. Nat Genet (2013) 4.71
An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet (2013) 4.69
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48
The functional spectrum of low-frequency coding variation. Genome Biol (2011) 4.42
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A (2011) 4.15
Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep (2013) 3.92
De novo copy number variants identify new genes and loci in isolated sporadic tetralogy of Fallot. Nat Genet (2009) 3.86
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
Mutations in TMEM216 perturb ciliogenesis and cause Joubert, Meckel and related syndromes. Nat Genet (2010) 3.66
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
PathSeq: software to identify or discover microbes by deep sequencing of human tissue. Nat Biotechnol (2011) 3.57
Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res (2009) 3.45
Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. Nucleic Acids Res (2004) 3.37
Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A (2008) 3.30
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet (2013) 3.19
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A (2012) 3.06
Making sense of cancer genomic data. Genes Dev (2011) 3.01
Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 2.94
RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics (2012) 2.94
ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics (2011) 2.90
Comparative gene marker selection suite. Bioinformatics (2006) 2.71
Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov (2014) 2.64
High order chromatin architecture shapes the landscape of chromosomal alterations in cancer. Nat Biotechnol (2011) 2.63
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov (2013) 2.61
High-resolution genomic and expression analyses of copy number alterations in breast tumors. Genes Chromosomes Cancer (2008) 2.46
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell (2007) 2.43
Comparing strategies to fine-map the association of common SNPs at chromosome 9p21 with type 2 diabetes and myocardial infarction. Nat Genet (2011) 2.42